Regeneron Pharmaceuticals Inc. (REGN)
Symbol Info
Listed Symbol REGN
Name Regeneron Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $6,293,951,000
Latest Fiscal EPS $21.30
Price Info
21 Day Moving Average $289.6495
21 Day EMA $292.740600
50 Day Moving Average $289.8054
50 Day EMA $293.051480
200 Day EMA $324.142520
200 Day Moving Average 342.120060
52 Week High $442.00
52 Week Low $271.37
52 Week Change $-24.044800
Alpha -0.008162
Beta 1.1166
Standard Deviation 0.093367
R2 0.168672
Periods 60
Share Information
10 Day Average Volume 808,262
20 Day Average Volume 726,984
30 Day Average Volume 735,693
50 Day Average Volume 684,724
Outstanding Shares 109,832,371
Float Shares 108,667,327
Percent Float 98.94%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 1,504
Institute Holdings Date 2019-09-30
Institute Bought Previous 3 Months 8,316,765
Institute Holdings Percent 95.900000
Institute Sold Previous 3 Months 12,142,406
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months -
Insider Holdings Percent 1.10%
Insider Sold Previous 3 Months -
Insiders Shares Owned 1,165,044
Price Change
7 Day Price Change $-0.5799866
7 Day Percent Change -0.19%
21 Day Price Change $26.7300110
21 Day Percent Change 9.77%
30 Day Price Change $15.1300050
30 Day Percent Change 5.31%
Month To Date Price Change $22.7900
Month To Date Percent 8.22%
90 Day Price Change $-2.899994
90 Day Percent Change -0.96%
Quarter To Date $22.790009
Quarter To Date Percent 8.22%
180 Day Price Change $-33.149994
180 Day Percent Change -9.94%
200 Day Price Change $-109.859985
200 Day Percent Change -26.79%
Year To Date $-73.31
Year To Date Percent -19.63%
Profile
Description Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has six marketed products: Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Zaltrap in colorectal cancer; Dupixent in atopic dermatitis and asthma; Libtayo in cutaneous squamous cell carcinoma; Arcalyst in CAPS; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal antibodies with Sanofi in immunology and cancer.
Details
Issue Type CS
Market Cap $32,970,579,450
Sec Type EQS
Auditor PricewaterhouseCoopers LLP
Total Shares Outstanding 109,832,371
CEO Leonard S. Schleifer
Employees 7,400
Last Audit UE
Classification
CIK 0000872589
Industry Biotechnology
Sector Healthcare
NAICS Pharmaceutical Preparation Manufacturing(325412)
Info
Address 777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
Website http://www.regeneron.com
Facisimile
Telephone +1 914 847-7000
Email manisha.narasimhan@regeneron.com
Key Ratios
Profitability
EBIT Margin 29.20
EBITDA Margin 31.7
Pre-Tax Profit Margin 31.6
Profit Margin Cont 27.84
Gross Margin 92.30
Profit Margin TOT 27.84
Income Statements
Revenue $5,295,949,000
Revenue Per Share $49.0441
Revenue 3 Years $7.15
Revenue 5 Years $16.86
Valuation Measures
PE Ratio 15.20
Enterprise Value $28,509,099,715
Price To Sales 6.120818
Price To Free Cash 19.300000
PE High Last 5 Years 197.4
Price To Book 3.1
Price To Cash Flow 13.9
PE Low Last 5 Years 27.3
Price To Tangible Book 3.1
Financial Strength
Total Debt To Equity 0.1
Int Coverage 69.1
Current Ratio 3.9
Leverage Ratio 1.3
Quick Ratio 3.0
Long Term Debt To Capital 0.07
Assets
Receivables Turnover 1.0
Invoice Turnover 0.50
Assets Turnover 0.20
Management Effectiveness
Return Assets 17.90
Return On Equity 24.43
Return On Capital 22.78
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
REGN
Regeneron ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.